Cortical α7 nicotinic acetylcholine receptor and β-amyloid levels in early Alzheimer disease

Milos D. Ikonomovic, Lynn Wecker, Eric E. Abrahamson, Joanne Wuu, Scott E. Counts, Stephen D. Ginsberg, Elliott J. Mufson, Steven T. DeKosky

Research output: Contribution to journalArticle

47 Citations (Scopus)

Abstract

Objective: To examine α7 nicotinic acetylcholine receptor (nAChR) binding and β-amyloid (Aβ) peptide load in superior frontal cortex (SFC) across clinical and neuropathological stages of Alzheimer disease (AD). Design: Quantitative measures of α7 nAChR by [3H] methyllycaconitine binding and Aβ concentration by enzyme-linked immunosorbent assay in SFC were compared across subjects with antemortem clinical classification of no cognitive impairment, mild cognitive impairment, or mild to moderate AD, and with postmortem neuropathological diagnoses. Setting: Academic medical center. Subjects: Twenty-nine elderly retired clergy. Main Outcome Measures: Quantitative measures of α7 nAChR binding and Aβ peptide concentration in SFC. Results: Higher concentrations of total Aβ peptide in SFC were associated with clinical diagnosis of mild to moderate AD (P = .02), lower Mini-Mental State Examination scores (P = .003), presence of cortical Aβ plaques (P = .02), and likelihood of AD diagnosis by the National Institute on Aging-Reagan criteria (P = .002). Increased α7 nAChR binding was associated with National Institute on Aging-Reagan diagnosis (P = .02) and, albeit weakly, the presence of cortical Aβ plaques (P = .08). There was no correlation between the 2 biochemical measures. Conclusions: These observations suggest that during the clinical progression from normal cognition to neurodegenerative disease state, total Aβ peptide concentration increases while α7 nAChRs remain relatively stable in SFC. Regardless of subjects' clinical status, however, elevated α7 nAChR binding is associated with increased Aβ plaque pathology, supporting the hypothesis that cellular expression of these receptors may be upregulated selectively in Aβ plaque-burdened brain areas.

Original languageEnglish
Pages (from-to)646-651
Number of pages6
JournalArchives of Neurology
Volume66
Issue number5
DOIs
StatePublished - May 1 2009
Externally publishedYes

Fingerprint

Nicotinic Receptors
Frontal Lobe
Amyloid
Alzheimer Disease
National Institute on Aging (U.S.)
Peptides
Clergy
Neurodegenerative Diseases
Cognition
Enzyme-Linked Immunosorbent Assay
Outcome Assessment (Health Care)
Alzheimer's Disease
Cortex
Pathology
Brain
Cognitive Dysfunction
Ronald Reagan

ASJC Scopus subject areas

  • Clinical Neurology

Cite this

Ikonomovic, M. D., Wecker, L., Abrahamson, E. E., Wuu, J., Counts, S. E., Ginsberg, S. D., ... DeKosky, S. T. (2009). Cortical α7 nicotinic acetylcholine receptor and β-amyloid levels in early Alzheimer disease. Archives of Neurology, 66(5), 646-651. https://doi.org/10.1001/archneurol.2009.46

Cortical α7 nicotinic acetylcholine receptor and β-amyloid levels in early Alzheimer disease. / Ikonomovic, Milos D.; Wecker, Lynn; Abrahamson, Eric E.; Wuu, Joanne; Counts, Scott E.; Ginsberg, Stephen D.; Mufson, Elliott J.; DeKosky, Steven T.

In: Archives of Neurology, Vol. 66, No. 5, 01.05.2009, p. 646-651.

Research output: Contribution to journalArticle

Ikonomovic, MD, Wecker, L, Abrahamson, EE, Wuu, J, Counts, SE, Ginsberg, SD, Mufson, EJ & DeKosky, ST 2009, 'Cortical α7 nicotinic acetylcholine receptor and β-amyloid levels in early Alzheimer disease', Archives of Neurology, vol. 66, no. 5, pp. 646-651. https://doi.org/10.1001/archneurol.2009.46
Ikonomovic, Milos D. ; Wecker, Lynn ; Abrahamson, Eric E. ; Wuu, Joanne ; Counts, Scott E. ; Ginsberg, Stephen D. ; Mufson, Elliott J. ; DeKosky, Steven T. / Cortical α7 nicotinic acetylcholine receptor and β-amyloid levels in early Alzheimer disease. In: Archives of Neurology. 2009 ; Vol. 66, No. 5. pp. 646-651.
@article{bb511866baad47ecbb7d93fe5a12b559,
title = "Cortical α7 nicotinic acetylcholine receptor and β-amyloid levels in early Alzheimer disease",
abstract = "Objective: To examine α7 nicotinic acetylcholine receptor (nAChR) binding and β-amyloid (Aβ) peptide load in superior frontal cortex (SFC) across clinical and neuropathological stages of Alzheimer disease (AD). Design: Quantitative measures of α7 nAChR by [3H] methyllycaconitine binding and Aβ concentration by enzyme-linked immunosorbent assay in SFC were compared across subjects with antemortem clinical classification of no cognitive impairment, mild cognitive impairment, or mild to moderate AD, and with postmortem neuropathological diagnoses. Setting: Academic medical center. Subjects: Twenty-nine elderly retired clergy. Main Outcome Measures: Quantitative measures of α7 nAChR binding and Aβ peptide concentration in SFC. Results: Higher concentrations of total Aβ peptide in SFC were associated with clinical diagnosis of mild to moderate AD (P = .02), lower Mini-Mental State Examination scores (P = .003), presence of cortical Aβ plaques (P = .02), and likelihood of AD diagnosis by the National Institute on Aging-Reagan criteria (P = .002). Increased α7 nAChR binding was associated with National Institute on Aging-Reagan diagnosis (P = .02) and, albeit weakly, the presence of cortical Aβ plaques (P = .08). There was no correlation between the 2 biochemical measures. Conclusions: These observations suggest that during the clinical progression from normal cognition to neurodegenerative disease state, total Aβ peptide concentration increases while α7 nAChRs remain relatively stable in SFC. Regardless of subjects' clinical status, however, elevated α7 nAChR binding is associated with increased Aβ plaque pathology, supporting the hypothesis that cellular expression of these receptors may be upregulated selectively in Aβ plaque-burdened brain areas.",
author = "Ikonomovic, {Milos D.} and Lynn Wecker and Abrahamson, {Eric E.} and Joanne Wuu and Counts, {Scott E.} and Ginsberg, {Stephen D.} and Mufson, {Elliott J.} and DeKosky, {Steven T.}",
year = "2009",
month = "5",
day = "1",
doi = "10.1001/archneurol.2009.46",
language = "English",
volume = "66",
pages = "646--651",
journal = "Archives of Neurology",
issn = "0003-9942",
publisher = "American Medical Association",
number = "5",

}

TY - JOUR

T1 - Cortical α7 nicotinic acetylcholine receptor and β-amyloid levels in early Alzheimer disease

AU - Ikonomovic, Milos D.

AU - Wecker, Lynn

AU - Abrahamson, Eric E.

AU - Wuu, Joanne

AU - Counts, Scott E.

AU - Ginsberg, Stephen D.

AU - Mufson, Elliott J.

AU - DeKosky, Steven T.

PY - 2009/5/1

Y1 - 2009/5/1

N2 - Objective: To examine α7 nicotinic acetylcholine receptor (nAChR) binding and β-amyloid (Aβ) peptide load in superior frontal cortex (SFC) across clinical and neuropathological stages of Alzheimer disease (AD). Design: Quantitative measures of α7 nAChR by [3H] methyllycaconitine binding and Aβ concentration by enzyme-linked immunosorbent assay in SFC were compared across subjects with antemortem clinical classification of no cognitive impairment, mild cognitive impairment, or mild to moderate AD, and with postmortem neuropathological diagnoses. Setting: Academic medical center. Subjects: Twenty-nine elderly retired clergy. Main Outcome Measures: Quantitative measures of α7 nAChR binding and Aβ peptide concentration in SFC. Results: Higher concentrations of total Aβ peptide in SFC were associated with clinical diagnosis of mild to moderate AD (P = .02), lower Mini-Mental State Examination scores (P = .003), presence of cortical Aβ plaques (P = .02), and likelihood of AD diagnosis by the National Institute on Aging-Reagan criteria (P = .002). Increased α7 nAChR binding was associated with National Institute on Aging-Reagan diagnosis (P = .02) and, albeit weakly, the presence of cortical Aβ plaques (P = .08). There was no correlation between the 2 biochemical measures. Conclusions: These observations suggest that during the clinical progression from normal cognition to neurodegenerative disease state, total Aβ peptide concentration increases while α7 nAChRs remain relatively stable in SFC. Regardless of subjects' clinical status, however, elevated α7 nAChR binding is associated with increased Aβ plaque pathology, supporting the hypothesis that cellular expression of these receptors may be upregulated selectively in Aβ plaque-burdened brain areas.

AB - Objective: To examine α7 nicotinic acetylcholine receptor (nAChR) binding and β-amyloid (Aβ) peptide load in superior frontal cortex (SFC) across clinical and neuropathological stages of Alzheimer disease (AD). Design: Quantitative measures of α7 nAChR by [3H] methyllycaconitine binding and Aβ concentration by enzyme-linked immunosorbent assay in SFC were compared across subjects with antemortem clinical classification of no cognitive impairment, mild cognitive impairment, or mild to moderate AD, and with postmortem neuropathological diagnoses. Setting: Academic medical center. Subjects: Twenty-nine elderly retired clergy. Main Outcome Measures: Quantitative measures of α7 nAChR binding and Aβ peptide concentration in SFC. Results: Higher concentrations of total Aβ peptide in SFC were associated with clinical diagnosis of mild to moderate AD (P = .02), lower Mini-Mental State Examination scores (P = .003), presence of cortical Aβ plaques (P = .02), and likelihood of AD diagnosis by the National Institute on Aging-Reagan criteria (P = .002). Increased α7 nAChR binding was associated with National Institute on Aging-Reagan diagnosis (P = .02) and, albeit weakly, the presence of cortical Aβ plaques (P = .08). There was no correlation between the 2 biochemical measures. Conclusions: These observations suggest that during the clinical progression from normal cognition to neurodegenerative disease state, total Aβ peptide concentration increases while α7 nAChRs remain relatively stable in SFC. Regardless of subjects' clinical status, however, elevated α7 nAChR binding is associated with increased Aβ plaque pathology, supporting the hypothesis that cellular expression of these receptors may be upregulated selectively in Aβ plaque-burdened brain areas.

UR - http://www.scopus.com/inward/record.url?scp=66249133352&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=66249133352&partnerID=8YFLogxK

U2 - 10.1001/archneurol.2009.46

DO - 10.1001/archneurol.2009.46

M3 - Article

C2 - 19433665

AN - SCOPUS:66249133352

VL - 66

SP - 646

EP - 651

JO - Archives of Neurology

JF - Archives of Neurology

SN - 0003-9942

IS - 5

ER -